Literature DB >> 27644598

Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F1 mice.

G Ronald Jenkins1, Taewon Lee2, Carrie L Moland1, Vikrant Vijay1, Eugene H Herman3, Sherry M Lewis4, Kelly J Davis5, Levan Muskhelishvili5, Susan Kerr6, James C Fuscoe1, Varsha G Desai7.   

Abstract

Sex is a risk factor for development of cardiotoxicity, induced by the anti-cancer drug, doxorubicin (DOX), in humans. To explore potential mechanisms underlying differential susceptibility to DOX between sexes, 8-week old male and female B6C3F1 mice were dosed with 3mg/kg body weight DOX or an equivalent volume of saline via tail vein once a week for 6, 7, 8, and 9 consecutive weeks, resulting in 18, 21, 24, and 27mg/kg cumulative DOX doses, respectively. At necropsy, one week after each consecutive final dose, the extent of myocardial injury was greater in male mice compared to females as indicated by higher plasma concentrations of cardiac troponin T at all cumulative DOX doses with statistically significant differences between sexes at the 21 and 24mg/kg cumulative doses. A greater susceptibility to DOX in male mice was further confirmed by the presence of cytoplasmic vacuolization in cardiomyocytes, with left atrium being more vulnerable to DOX cardiotoxicity. The number of TUNEL-positive cardiomyocytes was mostly higher in DOX-treated male mice compared to female counterparts, showing a statistically significant sex-related difference only in left atrium at 21mg/kg cumulative dose. DOX-treated male mice also had an increased number of γ-H2A.X-positive (measure of DNA double-strand breaks) cardiomyocytes compared to female counterparts with a significant sex effect in the ventricle at 27mg/kg cumulative dose and right atrium at 21 and 27mg/kg cumulative doses. This newly established mouse model provides a means to identify biomarkers and access potential mechanisms underlying sex-related differences in DOX-induced cardiotoxicity. Published by Elsevier Inc.

Entities:  

Keywords:  Apoptosis; Cardiotoxicity; DNA damage; Doxorubicin; Mouse model; Sex-based differences

Mesh:

Substances:

Year:  2016        PMID: 27644598     DOI: 10.1016/j.taap.2016.09.012

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  14 in total

1.  Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.

Authors:  Steven E Lipshultz; Eugene H Herman
Journal:  Cardiovasc Res       Date:  2018-02-01       Impact factor: 10.787

2.  Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.

Authors:  Timothy J Flanigan; Julie E Anderson; Ikram Elayan; Antiño R Allen; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

3.  Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity.

Authors:  Maurizio Viale; Graziella Vecchio; Massimiliano Monticone; Vittorio Bertone; Valentina Giglio; Irena Maric; Michele Cilli; Vittorio Bocchini; Aldo Profumo; Mirco Ponzoni; Laura Emionite; Mattia Rocco
Journal:  Pharm Res       Date:  2019-06-03       Impact factor: 4.200

Review 4.  Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group.

Authors:  Roberto Tofani Sant'Anna; Bruna Eibel; Melissa Medeiros Markoski; Clarissa Garcia Rodrigues; Felipe Borsu de Salles; Imarilde Inês Giusti; Ivo Abrahão Nesralla; Nance Beyer Nardi; Renato Abdala Karam Kalil
Journal:  Gene Ther       Date:  2019-07-05       Impact factor: 5.250

Review 5.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

6.  Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.

Authors:  Sibu P Kuruvilla; Gopinath Tiruchinapally; A Colleen Crouch; Mohamed E H ElSayed; Joan M Greve
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

7.  Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice.

Authors:  Marianne K O Grant; Davis M Seelig; Leslie C Sharkey; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2017-01-07       Impact factor: 5.027

Review 8.  Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.

Authors:  Becky Meiners; Chetan Shenoy; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2018-08-29       Impact factor: 5.027

9.  Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans.

Authors:  Caroline J Zeiss; Daniel M Gatti; Olga Toro-Salazar; Crystal Davis; Cathleen M Lutz; Francis Spinale; Timothy Stearns; Milena B Furtado; Gary A Churchill
Journal:  G3 (Bethesda)       Date:  2019-08-08       Impact factor: 3.154

Review 10.  HSP27 role in cardioprotection by modulating chemotherapeutic doxorubicin-induced cell death.

Authors:  Sivasubramanian Ramani; Sungkwon Park
Journal:  J Mol Med (Berl)       Date:  2021-03-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.